North America Erythropoietin Drugs Market

North America Erythropoietin Drugs Market Size & Growth (2024 to 2029)

The size of the North America Erythropoietin Drugs Market was valued at USD 3.78 billion in 2024. This value is estimated to grow at a CAGR of 9.6% and worth USD 5.98 billion by 2029 during the forecast period.

DRIVERS

The increasing prevalence of chronic diseases such as end-stage renal disease, cancer and Human Immunodeficiency Virus is expected to increase the demand for EPO stimulating agents, as these conditions can lead to anemia, which can deteriorating effects on bodies with pre-existing chronic diseases. The demand for erythropoietin (EPO) is expected to increase in the coming years to combat the increasing incidence of anemia.

According to the Centers for Disease Control and Prevention on Chronic Kidney Disease in the United States, an estimated 16% of adults in the United States, or 39 million people, suffered from chronic renal failure (CKD). CKD is more common in people 65 and older (39%) than in people 45 to 64 (14%) and 18 to 45 (8%). The erythropoietin (EPO) drugs market in North America is expected to grow during the forecast period owing to factors such as increase in the number of patients with anemia, favorable reimbursements, increased commercialization of biosimilars of the EPO and an increased incidence of chronic kidney disease or acute kidney injury.

RESTRAINTS

The constant evolution of newer and better drugs make it a major restrain affecting the market growth for upcoming years.

OPPORTUNITIES

Scientists are currently planning a randomized clinical trial to systematically study the effects of treating COVID-19 with erythropoietin. According to data from the Centers for Disease Control and Prevention, there are 1.2 million people in the United States living with HIV .These statistics clearly indicate that the demand of EPO drugs will increase during the forecast period.

EPO drugs have other beneficial effects that have a good impact of the COVID-19 affected people so during pandemic, it is expected to remain positive for the major companies in the erythropoietin drug market.

CHALLENGES

Side effects of EPO, such as high blood pressure, iron deficiency, and flu like symptoms, along with longer duration of EPO treatment are limiting market growth erythropoietin-based drugs.

This research report on the North America Erythropoietin Drugs Market has been segmented and sub-segmented into the following categories.

By Product

• Epoetin-alpha
• Epoetin-beta
• Darbepoetin-alfa
• Others

By Application

• Cancer
• Hematology
• Renal Diseases
• Neurology

By Drug Class

• Biologics
• Biosimilars

By Country

• The U.S.

• Canada
• Rest of North America

REGIONAL ANALYSIS

Due to the increasing prevalence of chronic diseases such as cancer, CKD, and HIV, North America accounted for lucrative growth demand of erythropoietin drug sales in 2019. The U.S had dominant share in the market share due to technological development, presence of major manufacturing units, less stringent government rules for drug approval due to presence of FDA and a large population that includes geriatric people above age 60 plus years who often have chronic diseases such as diabetic and hypertension etc.

Canada is a promising market for erythropoietin growth and most of the erythropoietin producing companies are now focusing on the Canadian market for market growth. The region has the greatest participation in the biosimilar industry, due to the development of biosimilars by the major manufacturers in these regions. In addition, the marketing models of erythropoietin biosimilars, readily available discounts, favorable government regulations, and awareness of the benefits of EPO therapies are contributing to the growth of the North America erythropoietin drug market in Canada. Additionally it is expected to have good progress in terms of revenue due to the increase in cases of cardiovascular diseases and rapidly aging population.

KEY MARKET PARTICIPANTS

Some of the notable companies operating in the North America erythropoietin drugs market are Amgen, Inc., Biocon Limited, Celltrion, Inc., Dr. Reddy's Laboratories Ltd., F. Hoffman-La Roche Ltd., Hospira, Inc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Inc., LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd.